Tag

Lipid Lowering Therapy

All articles tagged with #lipid lowering therapy

health28 days ago•4 min saved

Biannual Inclisiran Therapy Delivers Major LDL Cholesterol Reductions Across Trials

A systematic review and meta-analysis of nine randomized trials (6,355 participants) found inclisiran—given by subcutaneous injection at baseline, 3 months, then every six months—produces about a 49% greater LDL-C reduction versus placebo, with consistent benefit across backgrounds of lipid-lowering therapy including statins; its twice-yearly dosing may aid adherence and help statin-intolerant patients, though long-term cardiovascular outcomes are still being studied in ongoing ORION-4 and VICTORION-2P trials, and clinicians see inclisiran as complementary to statins rather than a replacement, with future work needed on safety, cost-effectiveness, and equitable access.

via Medscape|

#cardiovascular-disease #health #inclisiran

health3 years ago•7 min saved

Primary Prevention: The 'Striking' Benefit of Lowering Lipids.

A new analysis of the CLEAR Outcomes trial of bempedoic acid has shown a 30% relative risk reduction in the composite of cardiovascular death, myocardial infarction (MI), stroke, or coronary revascularization in high-risk primary prevention patients, two thirds of whom also had type 2 diabetes. The study's lead investigator, Dr. Steve Nissen, called the results "frankly striking" and emphasized the need for more attention to be paid to this group of patients, who are often not well treated. Nissen recommends that high-risk primary prevention patients, particularly those with type 2 diabetes, should be treated with a lipid-lowering drug, such as a statin or bempedoic acid.

via Medscape|

#bempedoic-acid #cardiovascular-disease #health

healthcare3 years ago•7 min saved

Managing Cardiovascular Disease Through Cholesterol Reduction.

Patients with cardiovascular diseases often have much higher LDL cholesterol levels than recommended in the guidelines, and only a minority of patients receive combination therapy, and PCSK9 inhibitors are rarely prescribed. The recent SANTORINI study once again highlights the need for the intensive application of lipid-lowering drugs. The DA-VINCI study showed a massive discrepancy between the target levels of LDL cholesterol stipulated in the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines and the levels achieved in clinical practice.

via Medscape|

#cardiovascular-disease #cholesterol #guidelines